You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

Isis Pharmaceuticals Inc down slightly

Isis Pharmaceuticals Inc is down just (U.S.)$0.06 today to (U.S.)$64.75. Shares have lost 5.09% over the last five days, but have gained 4.88% over the last year to date. This security has outperformed the S&P 500 by 38.87% during the last year.

Key company metrics

Open(U.S.) $64.05

Previous close(U.S.) $64.81

High(U.S.) $67.17

Low(U.S.) $64.00

Bid / Ask(U.S.) $64.77 / (U.S.) $64.83

YTD % change+4.88%

Volume2,036,590

Average volume (10-day)3,859,924

Average volume (1-month)3,015,294

Average volume (3-month)3,336,294

52-week range(U.S.) $22.25 to (U.S.) $77.80

Beta1.49

Trailing P/ENegative, not meaningful

P/E 1 year forwardNegative, not meaningful

Forward PEGNegative, not meaningful

Indicated annual dividend--

Dividend yield0.00%

Trailing EPS(U.S.) -$0.33

Updated March 31 1:56 PM EDT. Delayed by at least 15 minutes.

Key company metrics

Open(U.S.) $64.05

Previous close(U.S.) $64.81

High(U.S.) $67.17

Low(U.S.) $64.00

Bid / Ask(U.S.) $64.77 / (U.S.) $64.83

YTD % change+4.88%

Volume2,036,590

Average volume (10-day)3,859,924

Average volume (1-month)3,015,294

Average volume (3-month)3,336,294

52-week range(U.S.) $22.25 to (U.S.) $77.80

Beta1.49

Trailing P/ENegative, not meaningful

P/E 1 year forwardNegative, not meaningful

Forward PEGNegative, not meaningful

Indicated annual dividend--

Dividend yield0.00%

Trailing EPS(U.S.) -$0.33

Updated March 31 1:56 PM EDT. Delayed by at least 15 minutes.

About

Isis Pharmaceuticals, Inc., is engaged in antisense technology, exploiting a drug discovery platform to create a pipeline of drugs. The Company’s primary activity is to discover

Continue reading

and develop antisense drugs. The antisense drugs are used to treat a wide range of diseases, including severe and rare, cardiovascular, neurologic and metabolic diseases and cancer. The Company’s flagship product, KYNAMRO (mipomersen sodium) injection, is on the market in the United States for patients with homozygous familial hypercholesterolemia, or HoFH. Patients with HoFH are at high cardiovascular risk and cannot reduce their low-density lipoprotein cholesterol, or LDL-C, sufficiently with currently available lipid-lowering therapies As of December 2013 The Company has three generation 2.5 drugs in development, ISIS-STAT3Rx, ISIS-ARRx and ISIS-FVIIRx. As of December 2013 the Company has a pipeline of 31 drugs in development.

Profit

Net Profit (TTM)

-18.20%

Isis Pharmaceuticals Inc has a net profit margin of -18.20%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit. Company Books

Restrictions

All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. Thomson Reuters is not liable for any errors or delays in Thomson Reuters content, or for any actions taken in reliance on such content. ‘Thomson Reuters’ and the Thomson Reuters logo are trademarks of Thomson Reuters and its affiliated companies.